Log In

 

Company Name : Laurus Labs Ltd.

Tuesday, February 14, 2017 12:36AM IST (7:06PM GMT)

(BW)(LAURUS-LABS-LTD.)

Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


Hyderabad, India

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India announces its 9M & Q3 FY17 results.

 

9M FY17 results:

 
  • Total Revenue grew by 9.7% to Rs.14,459 mn from Rs.13,179 mn
  • EBITDA increased by 23.1% to Rs.3,199 mn versus Rs.2,598 mn
  • PAT higher by 40.5% to Rs.1,277 mn from Rs.909 mn
  • EPS (Diluted) for the period stood at Rs.12.9 per share (not annualised)

Q3 FY17 results:

 
  • Total Revenue grew by 12.3% to Rs.5,054 mn from Rs.4,501 mn
  • EBITDA increased by 9.4% to Rs.1,115 mn versus Rs.1,019 mn
  • PAT higher by 17.5% to Rs.472 mn from Rs.402 mn
  • EPS (Diluted) for the period stood at Rs.4.7 per share (not annualised)

Business Highlights – 9M FY17:

 
  • Prepayment of long term loans of Rs.2,263 million from IPO proceeds, Rs.585 million spent on general corporate purposes after meeting IPO expenses of Rs.150 million.
  • Capex investments in first nine months Rs.2,584 million.
  • R & D opex investments Rs.773 million and 5.3% as percentage of sales during Apr – Dec, 2016
  • In partnership with Laurus, Natco has launched Velpatasivir (Hep-C) product in Nepal and is geared up for launch in India upon approval.
  • As on Dec 2016, the Company has filed 202 patent applications and 37 patents granted.
  • Expansion of R & D centre at Hyderabad completed.
  • As on date filed 2 ANDAs and in addition completed 4 product validations.
  • Capacity expansion of 5 billion tablets is expected to complete by end Mar 17.
  • US FDA and WHO inspection scheduled during March 2017 for Unit 2.
  • FDF opex investments are Rs.821 million which includes Rs.253 million relating to the R& D during Apr – Dec, 2016
  • Unit 5 (dedicated manufacturing facility for Aspen) is inaugurated and is operational in Nov ‘16
  • Laurus signed manufacturing and supply agreement for Oncology NCE for clinical phase and commercial supplies
  • Dr. Satyanarayana Chava nominated as one of the members of US pharmacopeia Board of Trustees (BoT)
  • Laurus Labs received Pharmaexcil patent Silver Award for the contribution in the category of Bulk Drugs /APIs to India’s Pharmaceutical Exports during the year 2015-16

For more information about us, please visit http://www.lauruslabs.com.

 

 

 

 


Click here for Media Contact Details
CONTACTS : Laurus Labs Ltd.Pavan Kumar N, +91 40 3980 4380mediarelations@lauruslabs.com

More News from Laurus Labs Ltd.

19/05/2017 8:10PM

लॉरस लैब्स का कर के बाद लाभ (पीएटी) 40% बढ़ा; बोर्ड ने 15% के लाभांश की सिफारिश की

अनुसंधान और विकास आधारित भारत की अग्रणी फार्मास्यूटिकल कंपनी लॉरस लैब्स लिमिटेड (लॉरस) ने चौथी तिमाही और वित्त वर्ष 17 के अपने परिणामों की घोषणा की है।   विव17 लॉरस ने रिपोर्ट ...

19/05/2017 3:45PM

Laurus Labs PAT Grows by 40%; Board Recommends a Dividend of 15%

Laurus Labs Ltd. (Laurus), a leading R&D driven pharmaceutical company in India announces its Q4 & FY17 results.   FY17 Laurus reported:   Total Revenue rose 6.6% to Rs.18,919 mn as compared ...

14/02/2017 1:03PM

लॉरस लैब्स ने सफल आईपीओ के बाद पहले तिमाही परिणाम में तीसरी तिमाही के दौरान मज़बूत विकास का प्रदर्शन किया

अनुसंधान और विकास आधारित भारत की अग्रणी फार्मास्यूटिकल कंपनी लॉरस लैब्स लिमिटेड (लॉरस), ने वित्त वर्ष 17 के नौ महीने और तीसरी तिमाही के नतीजों की घोषणा की है। विव 17 के 9 महीनों के नतीजे : कुल ...

Similar News

20/09/2017 6:40PM

6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England

The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP, the Secretary ...

No Image

20/09/2017 6:15PM

Biosafe Defenses LLC Announces a New Groundbreaking Disinfectant after 10 Years of Research

Biosafe Defenses LLC (formerly Biosafe Technologies LLC), the world leader in the creation of an entirely new class of light-activated disinfectants, antibacterials and biocides for the home, hospitals and industry, has ...